Abstract
Glutamate was identified as the main excitatory neurotransmitter in the mammalian central nervous system (CNS) following the observation in the early 1950s that glutamate can induce seizure activity and excite neurons in the mammalian brain. Over the last two decades, selective ligands, including competitive agonists and antagonists and allosteric modulators, have been developed to further investigate the functional role of glutaminergic receptors. Glutamate released from synapses can activate ligand-gated cation channels at postsynaptic cells to mediate fast postsynaptic potentials. These ion channel-forming ionotropic glutamate receptors (iGluRs) are divided into N-methyl-d-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-isoxazole-4-prorionate (AMPA), and kainate (KA) receptors. While only 20–30 % of the amino acid sequence is shared among these receptor subtypes, they share similar structural features and their activity is based on specific pharmacological preference. In this chapter, we will describe the structure and composition of iGluRs and infer their pharmacology, with a particular focus on their role in the CNS and their relevance to the pathogenesis of neurodegenerative diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Addae, J. I., Evans, S. M., et al. (2000). NMDA-induced changes in a cortical network in vivo are prevented by AMPA. Brain Research, 869(1–2), 211–215.
Alt, A., Weiss, B., et al. (2004). Pharmacological characterisation of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology, 46, 793–806.
Araki, T., Kumagai, T., et al. (2000). Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice. Metabolic Brain Disease, 15(3), 193–201.
Araque, A., Sanzgiri, R. P., et al. (1998). Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. The Journal of Neuroscience, 18(17), 6822–6829.
Armstrong, N., Sun, Y., et al. (1998). Structure of a glutamate-receptor ligand binding core in complex with kainate. Nature, 395, 913–917.
Bamberger, M. E., & Landreth, G. E. (2001). Microglial interaction with beta-amyloid: Implications for the pathogenesis of Alzheimer’s disease. Microscopy Research and Technique, 54(2), 59–70.
Barnum, C., & Tansey, M. (2010). Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Progress in Brain Research, 184, 113–132.
Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Annals of the New York Academy of Sciences, 991, 120–131.
Beal, M. F., Kowall, N. W., et al. (1986). Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature, 321(6066), 168–171.
Beaton, J. A., Stemsrud, K., et al. (1992). Identification of a novel N-methyl-d-aspartate receptor population in the rat medial thalamus. Journal of Neurochemistry, 59(2), 754–757.
Bergeron, R., Meyer, T. M., et al. (1998). Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15730–15734.
Berliocchi, L., Bano, D., et al. (2005). Ca2+ signals and death programmes in neurons. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 360, 2255–2258.
Birch, P., Grossman, C., et al. (1988). 6,7-Dintro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychine-insensitive glycine receptor. European Journal of Pharmacology, 156, 177–180.
Bleakman, D., Gates, M., et al. (2002). Kainate receptor agonists, antagonists and allosteric modulators. Current Pharmaceutical Design, 8, 873–885.
Blennow, K., de Leon, M. J., et al. (2006). Alzheimer’s disease. Lancet, 368(9533), 387–403.
Boillee, S., Vande Velde, C., et al. (2006). ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron, 52(1), 39–59.
Boillee, S., Yamanaka, K., et al. (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 312(5778), 1389–1392.
Borges, K., & Dingledine, R. (1998). AMPA receptors: Molecular and functional diversity. Progress in Brain Research, 116, 153–170.
Bowie, D., & Mayer, M. (1995). Inward rectification of both AMPA and kainate subtype glutamate receptors generated by polyamine-mediated ion channel block. Neuron, 15, 453–462.
Braidy, N., Grant, R., et al. (2009). Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotoxicity Research, 16, 77–86.
Bristow, L., Hutson, P., et al. (1996). Anticonvulsant and behavioural profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-d-aspartate receptor complex. The Journal of Pharmacology and Experimental Therapeutics, 279, 492–501.
Bruyn, R. P., & Stoof, J. C. (1990). The quinolinic acid hypothesis in Huntington’s chorea. Journal of the Neurological Sciences, 95(1), 29–38.
Budd, S. L., Tenneti, L., et al. (2000). Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proceedings of the National Academy of Sciences of the United States of America, 97(11), 6161–6166.
Butterfield, D. A. (1997). β-Amyloid associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer’s disease. Chemical Research in Toxicology, 10, 495–506.
Carriedo, S., Yin, H., et al. (1996). Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. The Journal of Neuroscience, 16, 4069–4079.
Catts, S. V., Ward, P. B., et al. (1997). Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. The Australian and New Zealand Journal of Psychiatry, 31(1), 17–26.
Ceresoli-Borroni, G., Guidetti, P., et al. (1999). Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. Journal of Neural Transmission, 106(3–4), 229–242.
Chatterton, J. E., Awobuluyi, M., et al. (2002). Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature, 415(6873), 793–798.
Chen, Q., Harris, C., et al. (1995). Glutamate-mediated excitotoxic death of cultured striated neurons is mediated by non-NMDA receptors. Experimental Neurology, 136, 212–224.
Chen, Y., Brew, B. J., et al. (2011). Characterisation of the kynurenine pathway in NSC-34 cell line: Implications for amyotropic lateral sclerosis. Journal of Neurochemistry, 118, 816–825.
Christie, J. M., Jane, D. E., et al. (2000). Native N-methyl-d-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. The Journal of Pharmacology and Experimental Therapeutics, 292(3), 1169–1174.
Clements, J., & Westbrook, G. L. (1991). Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-d-aspartate receptor. Neuron, 7, 606–613.
Colwell, C. S., Altemus, K. L., et al. (1996). Regulation of N-methyl-d-aspartate-induced toxicity in the neostriatum: A role for metabotropic glutamate receptors? Proceedings of the National Academy of Sciences of the United States of America, 93(3), 1200–1204.
Comoletti, D., Muzio, V., et al. (2001). Nitric oxide produced by non-motoneuron cells enhances rat embryonic motoneuron sensitivity to excitotoxins: Comparison in mixed neuron/glia or purified cultures. Journal of the Neurological Sciences, 192(1–2), 61–69.
Conti, F., DeBiasi, S., et al. (1996). Expression of NR1 and NR2A/B subunits of the NMDA receptor in cortical astrocytes. Glia, 17(3), 254–258.
Conti, F., Barbaresi, P., et al. (1999). Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex. Cerebral Cortex, 9(2), 110–120.
Contractor, A., Swanson, G., et al. (2000). Identification of the kainate receptor subunits underlying modulation of excitatory synaptic transmission in the CA3 region of the hippocampus. The Journal of Neuroscience, 20, 8269–8278.
Dannhardt, G., & Kohl, B. K. (1998). The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications. Current Medicinal Chemistry, 5(4), 253–263.
Danysz, W. (2002). CX-516 cortex pharmaceuticals. Current Opinion in Investigational Drugs, 3, 1081–1088.
Das, S., Sasaki, Y., et al. (1998). Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature, 393, 377–381.
De Carvalho, L. P., Bochet, P., et al. (1996). The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochemistry International, 28(4), 445–452.
Dingledine, R., & McBain, C. J. (1994). Excitatory amino acid transmitters. In G. J. Siegel, B. W. Agranoff, & R. W. Albers (Eds.), Basic neurochemistry: Molecular, cellular and medical aspects (pp. 367–387). New York: Raven Press.
Dingledine, R., Borges, K., et al. (1999). The glutamate receptor ion channels. Pharmacological Reviews, 51(1), 7–61.
Dodd, P. R. (2002). Excited to death: Different ways to lose your neurones. Biogerontology, 3(1–2), 51–56.
Doggrell, S. (2003). Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease? Expert Opinion on Pharmacotherapy, 4(10), 1857–1860.
Ellison, D. W., Beal, M. F., et al. (1987). Amino acid neurotransmitter abnormalities in Huntington’s disease and the quinolinic acid animal model of Huntington’s disease. Brain, 110(Pt 6), 1657–1673.
Estevez, A., Stutzmann, J., et al. (1995). Protective effect of riluzole on excitatory amino-acid mediated neurotoxicity in motoneurons-enriched cultures. European Journal of Pharmacology, 280, 47–53.
Estrada Sanchez, A., Mejia-Toiber, J., et al. (2008). Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Archives of Medical Research, 39, 265–276.
Farlow, M. R. (2004). NMDA receptor antagonists. A new therapeutic approach for Alzheimer’s disease. Geriatrics, 59(6), 22–27.
Ferrante, R. J., Kowall, N. W., et al. (1993). Excitotoxin lesions in primates as a model for Huntington’s disease: Histopathologic and neurochemical characterization. Experimental Neurology, 119(1), 46–71.
Ferris, S. H. (2003). Evaluation of memantine for the treatment of Alzheimer’s disease. Expert Opinion on Pharmacotherapy, 4(12), 2305–2313.
Figueredo-Cardenas, G., Anderson, K. D., et al. (1994). Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Experimental Neurology, 129(1), 37–56.
Finlayson, K., Witchel, H., et al. (2004). Acquired QT interval prolongation and HERG: Implications for drug discovery and development. European Journal of Pharmacology, 500, 129–142.
Foster, A. C., Collins, J. F., et al. (1983). On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology, 22(12A), 1331–1342.
Foster, A. C., Gill, R., et al. (1987). Systemic administration of MK-801 prevents N-methyl-d-aspartate-induced neuronal degeneration in rat brain. Neuroscience Letters, 76(3), 307–311.
Foster, A. C., Gill, R., et al. (1988). Neuroprotective effects of MK-801 in vivo: Selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. The Journal of Neuroscience, 8(12), 4745–4754.
Foster, A. C., Kemp, J. A., et al. (1992). Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-d-aspartate receptor from rat brain. Molecular Pharmacology, 41(5), 914–922.
Gallarda, T., & Loo, H. (2004). Memantine (Ebixa): A new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer’s disease. Encephale, 30(1), 69–79.
Gallyas, F., Ball, S., et al. (2003). Assembly and cell surface expression of KA-2 subunit-containing kainate receptors. Journal of Neurochemistry, 86, 1414–1427.
Gardoni, F., & Di Luca, M. (2006). New targets for pharmacological intervention in the glutamatergic synapse. European Journal of Pharmacology, 545(1), 2–10.
Geiger, J., Melcher, T., et al. (1995). Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principals neurons and interneurons in rat CNS. Neuron, 15, 193–204.
Guillemin, G. J. (2003). Microglial activation. In ANPP (Ed.), Functional neuroanatomy. Microglia (Vol. 7, p. 4.1). Paris: ANPP.
Guillemin, G., Smythe, G., et al. (2004). Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes and neurons. Glia, 49, 15–23.
Guillemin, G. J., Brew, B. J., et al. (2005). Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathology and Applied Neurobiology, 31(4), 395–404.
Guillemin, G. J., Brew, B. J. et al. (2007). Mass spectrometric detection of quinolinic acid in microdissected Alzheimer’s disease plaques. International Congress Series, K. Takai. 1304, 404–408.
Gurney, M. E., Fleck, T. J., et al. (1998). Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 50(1), 62–66.
Hague, S., Klaffe, S., et al. (2005). Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1058–1063.
Hartley, D. M., Monyer, H., et al. (1990). 7-Chlorokynurenate blocks NMDA receptor-mediated neurotoxicity in murine cortical culture. The European Journal of Neuroscience, 2(4), 291–295.
Hartmann, T. (1999). Intracellular biology of Alzheimer’s disease amyloid beta peptide. European Archives of Psychiatry and Clinical Neuroscience, 249(6), 291–298.
Hertz, L., Dringen, R., et al. (1999). Astrocytes: Glutamate producers for neurons. Journal of Neuroscience Research, 57(4), 417–428.
Hollander, D., Pradas, J., et al. (1992). Long-term high dose dextromethorphan in amyotropic lateral sclerosis. Annals of Neurology, 32, 280.
Hollander, D., Pradas, J., et al. (1994). High-dose dextromethorphan in amyotropic lateral sclerosis: Phase I safety and pharmacokinetic studies. Annual Review of Neuroscience, 36, 920–924.
Honer, M., Benke, D., et al. (1998). Differentiation of glycine antagonist sites of N-methyl-d-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. The Journal of Biological Chemistry, 273(18), 11158–11163.
Hsieh, M., Gu, S., et al. (2012). Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Behavioural Brain Research, 229, 41–47.
Hugon, J., & Vallet, J. (1990). Abnormal distribution of phosphorylated neurofilaments in neuronal degeneration induced by kainic acid. Neuroscience Letters, 119, 45–48.
Hugon, J., Ludolph, A., et al. (1988). Studies on the aetiology and pathogenesis of motor neurons diseases. II. Clincial and electrophysiologica features of pyramidal dysfunction in macaques fed Lathyrus sativus and IDPN. Neurology, 38, 435–442.
Hwang, J. Y., Kim, Y. H., et al. (1999). N-Methyl-d-aspartate receptor blockade induces neuronal apoptosis in cortical culture. Experimental Neurology, 159, 124–130.
Jane, D. E., Olverman, H., et al. (1994). Agonists and competitive antagonists: Structure activity and molecular modelling studies. In G. L. Collingridge & J. Watkins (Eds.), The NMDA receptor. New York: Oxford University Press.
Javitt, D. C., & Zukin, S. (1990). The role of excitatory amino acids in neuropsychiatric illness. The Journal of Neuropsychiatry and Clinical Neurosciences, 2, 44–52.
Jhamandas, K. H., Boegman, R. J., et al. (2000). Excitotoxicity of quinolinic acid: Modulation by endogenous antagonists. Neurotoxicity Research, 2(2–3), 139–155.
Kato, T. (2004). Memantine: A therapeutic drug for Alzheimer’s disease and the comparison with MK-801. Folia Pharmacologica Japan, 124, 145–151.
Kawamata, J., & Shimohama, S. (2002). Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer’s disease. Journal of Alzheimer's Disease, 4(2), 71–76.
Kemp, J. A., & Leeson, P. (1993). The glycine site of the NMDA receptor – Five years on. Trends in Pharmacological Sciences, 14, 20–25.
Kemp, J. A., Foster, A. C., et al. (1988). 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America, 85, 6547–6550.
Kerchner, G., Wilding, T., et al. (2002). Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. The Journal of Neuroscience, 22, 8010–8017.
Kew, J. N. C., & Kemp, J. A. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology, 179, 4–29.
Kew, J., Koester, A., et al. (2000). Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. The Journal of Neuroscience, 20, 4037–4049.
Kloda, A., Clements, J., et al. (2004). Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-d-aspartate receptors. Molecular Pharmacology, 65, 1386–1396.
Lazzaro, J., Paternain, A., et al. (2002). Functional characterisation of CP-465,022, a selective, non-competitive AMAP receptor antagonist. Neuropharmacology, 42, 143–153.
Lee, M., Ting, K., et al. (2011). Characterisation of the expression of NMDA receptors in human astrocytes. PloS One, 5(11), e14123.
Lerma, J., Paternain, A., et al. (2001). Molecular physiology of kainate receptors. Physiological Reviews, 81, 971–998.
Levine, M., Klapstein, G., et al. (1999). Enhanced sensitivity to N-methyl-d-aspartate receptor activation and knockdown mouse models of Huntington’s disease. Journal of Neuroscience Research, 58, 515–532.
Liu, S., & Cull-Candy, S. (2002). Activity-dependent change in AMPA receptor properties in cerebellar stellate cells. The Journal of Neuroscience, 22, 3881–3889.
Liu, Q., Xu, Q., et al. (2004). Astrocyte-mediated activation of neuronal kainate receptors. Proceedings of the National Academy of Sciences of the United States of America, 101, 3172–3177.
Loftis, J. M., & Janowsky, A. (2003). The N-methyl-d-aspartate receptor subunit NR2B: Localization, functional properties, regulation, and clinical implications. Pharmacology & Therapeutics, 97(1), 55–85.
Luqquin, M., Obeso, J., et al. (1993). The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. European Journal of Pharmacology, 235, 297–300.
Matsuda, K., Fletcher, M., et al. (2003). Specific assembly with the NMDA receptor 3B subunit controls surface expression and calcium permeability of NMDA receptors. The Journal of Neuroscience, 23(31), 10064–10073.
Mattson, M. P. (2004). Pathway towards and away from Azheimer’s disease. Nature, 430, 630–639.
Mayer, M., & Armstrong, N. (2004). Structure and function of glutamate receptor ion channels. Annual Review of Physiology, 66, 161–181.
McBain, C., & Mayer, M. (1994). N-Methyl-d-aspartic acid receptor structure and function. Physiological Reviews, 74, 723–760.
Miller, R. G., Mitchell J. D. et al. (2007). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane Database of Systematic Reviews, (1), CD001447.
Monyer, H., Sprengel, R., et al. (1992). Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science, 256(5060), 1217–1221.
Monyer, H., Burnashev, N., et al. (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron, 12(3), 529–540.
Mosley, R., Benner, E., et al. (2006). Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease. Clinical Neuroscience Research, 6(5), 261–281.
Nakai, M., Qin, Z., et al. (2000). NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: Differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117. Brain Research, 859(2), 207–216.
Nishi, M., Hinds, H., et al. (2001). Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. The Journal of Neuroscience, 21(23), RC185.
Olney, J. W. (1978). Neurotoxicity of excitatory amino acids. In E. G. McGeer, J. W. Olney, & P. L. McGeer (Eds.), Kainic acid as a tool in neurobiology (pp. 95–112). New York: Raven Press.
Parameshwaran, K., Dhanasekaran, M., et al. (2008). Amyloid beta peptides and glutamatergic synaptic dysregulation. Experimental Neurology, 210, 7–13.
Pierson, J., Norris, J., et al. (2004). Molecular profiling of experimental Parkinson’s disease: Direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. Journal of Proteome Research, 3(2), 289–295.
Priestley, T., Horne, A. L., et al. (1990). The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rate cortical cell cultures. Brain Research, 531, 183–188.
Priestley, T., Ochu, E., et al. (1994). Subtypes of NMDA receptor in neurons cultured from rat brain. NeuroReport, 5, 1763–1765.
Priestley, T., Laughton, P., et al. (1995). Pharmacological properties of recombinant human N-methyl-d-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Molecular Pharmacology, 48(5), 841–848.
Rae, C., Moussa, C. E., et al. (2006). A metabolomic approach to ionotropic glutamate receptor subtype function: A nuclear magnetic resonance in vitro investigation. Journal of Cerebral Blood Flow & Metabolism, 8, 1005–1017.
Rahman, A., Ting, K., et al. (2009). The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PloS One, 4(7), e6344.
Roche, K. W., Standley, S., et al. (2001). Molecular determinants of NMDA receptor internalisation. Nature Neuroscience, 4, 794–802.
Rogawski, M. A., Gryder, D., et al. (2003). GluR5 kainate receptors, seizures, and the amygdala. Annals of the New York Academy of Sciences, 985, 150–162.
Rosenmund, C., Stern-Bach, Y., et al. (1998). The tetrameric structure of a glutamate receptor channel. Science, 280, 1596–1599.
Rothstein, J. D. (1995). Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clinical Neuroscience, 3(6), 348–359.
Seeburg, P. H., & Hartner, J. (2003). Regulation of ion channel/neurotransmitter receptor function by RNA editing. Current Opinion in Neurobiology, 13, 279–283.
Seeburg, P. H., Burnashev, N., et al. (1995). The NMDA receptor channel: Molecular design of a coincidence detector. Recent Progress in Hormone Research, 50, 19–34.
Solyom, S., & Tarnawa, I. (2002). Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Current Pharmaceutical Design, 8, 913–939.
Stensbol, T., Madsen, U., et al. (2002). The AMPA receptor binding site: Focus on agonists and competitive antagonists. Current Pharmaceutical Design, 8, 857–872.
Stewart, G. R., Olney, J. W., et al. (1991). Excitotoxicity in the embryonic chick spinal cord. Annals of Neurology, 30, 758–766.
Stone, T. W. (2001). Endogenous neurotoxins from tryptophan. Toxicon, 39(1), 61–73.
Sun, Y., Savanenin, A., et al. (2001). Polyglutamine-expanded huntingtin promotes sensitisation of N-methyl-d-aspartate receptors via post-synaptic density 95. The Journal of Biological Chemistry, 276, 24713–24718.
Tolle, T., Berthele, A., et al. (1993). The differential expression of NMDA and non-NMDA receptor subunits in the rat spinal cord and periaqueductal gray. The Journal of Neuroscience, 13, 5009–5028.
Turski, L., Huth, A., et al. (1998). ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proceedings of the National Academy of Sciences of the United States of America, 95, 10960–10965.
Williams, T., Day, N., et al. (1997). Calcium permeable AMPA receptors: A molecular basis for selective vulnerability in motor neurone disease. Annals of Neurology, 42, 200–207.
Wong, P., Cai, H., et al. (2002). Genetically engineered mouse models of neurodegenerative diseases. Nature Neuroscience, 5, 663–669.
Yu, W., Sun, Y., et al. (2011). The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Human Molecular Genetics, 20(16), 3227–3240.
Zhang, H., Li, Q., et al. (2008). Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington’s disease. Neurobiology of Disease, 2008(31), 80–88.
Zoccolella, S., Beghi, E., et al. (2007). Riluzole and amyotrophic lateral sclerosis survival: A population-based study in southern Italy. European Journal of Neurology, 14(3), 262–268.
Acknowledgments
This work was supported by the NHMRC Capacity Building Grant to Prof Perminder Sachdev. Nady Braidy is the recipient of an Alzheimer’s Australia Viertel Foundation Postdoctoral Research Fellowship at the University of New South Wales. We sincerely thank the Rebecca Cooper Medical Research Foundation for ongoing financial support of our research.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Braidy, N., Poljak, A., Jayasena, T., Guillemin, G.J., Sachdev, P. (2014). Ionotropic Receptors in the Central Nervous System and Neurodegenerative Disease. In: Kostrzewa, R. (eds) Handbook of Neurotoxicity. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5836-4_126
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5836-4_126
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5835-7
Online ISBN: 978-1-4614-5836-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences